索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]孙帅锋 刘巍.心肌纤维化病理机制及诊疗策略进展[J].国际心血管病杂志,2020,05:264-267.
点击复制

心肌纤维化病理机制及诊疗策略进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2020年05期
页码:
264-267
栏目:
综述
出版日期:
2020-10-15

文章信息/Info

Title:
-
作者:
孙帅锋 刘巍
150000 哈尔滨医科大学第四附属医院心血管内四科
Author(s):
-
关键词:
心肌纤维化;  胶原蛋白;  心肌成纤维细胞;  诊疗策略
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2020.05.003
文献标识码:
-
摘要:
心肌纤维化可引发心肌细胞外基质的病理性重构,导致纤维化瘢痕形成,这些瘢痕通过增加心肌间质僵硬度降低射血分数,阻滞心电传导,从而引起多种心脏功能障碍,甚至死亡。该文介绍了心肌纤维化的基本病理机制、诊断方法及有效延缓或阻止心肌纤维化进展的策略。
Abstract:
-

参考文献/References

[1] Disertori M, Masè M, Ravelli F. Myocardial fibrosis predicts ventricular tachyarrhythmias[J]. Trends Cardiovasc Med, 2017, 27(5):363-372.
[2] Writing Group Members, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics—2016 update: a report from the american heart association[J]. Circulation, 2016, 133(4):e38-e360.
[3] Murtha LA, Schuliga MJ, Mabotuwana NS, et al. The processes and mechanisms of cardiac and pulmonary fibrosis[J]. Front Physiol, 2017, 8:777.
[4] Graham-Brown MP, Patel AS, Stensel DJ, et al. Imaging of myocardial fibrosis in patients with end-stage renal disease: current limitations and future possibilities[J]. Biomed Res Int, 2017, 2017:5453606.
[5] De Jong S, Van Veen TA, Van Rijen HV, et al. Fibrosis and cardiac arrhythmias[J]. Cardiovasc Pharmacol, 2011, 57(6):630-638.
[6] Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis[J]. Cell Mol Life Sci, 2014, 71(4):549-574.
[7] Brauchle E, Kasper J, Daum R, et al. Biomechanical and biomolecular characterization of extracellular matrix structures in human colon carcinomas[J]. Matrix Biol, 2018, 68-69:180-193.
[8] Rog-Zielinska EA, Norris RA, Kohl P, et al. The living scar—cardiac fibroblasts and the injured heart[J]. Trends Mol Med, 2016, 22(2):99-114.
[9] Moore-Morris T, Guimarães-Camboa N, Banerjee I, et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis[J]. J Clin Invest, 2014, 124(7):2921-2934.
[10] Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased hearts[J]. J Cardiovasc Pharmacol, 2011, 57(4):380-388.
[11] Jellis C, Martin J, Narula J, et al. Assessment of nonischemic myocardial fibrosis[J]. J Am Coll Cardiol, 2010, 56(2):89-97.
[12] 李健, 刘景旺, 王守红, 等. 心血管磁共振成像在肥厚型心肌病患者心肌纤维化及心室功能评估中的应用[J]. 中国医刊, 2020, 55(7):790-792.
[13] Da Costa AWF, Do Carmo Neto JR, Braga YLL, et al. Cardiac Chagas disease: MMPs, TIMPs, galectins, and TGF-β as tissue remodelling players[J]. Dis Markers, 2019, 2019:3632906
[14] Zhang N, Wei WY, Li LL, et al. Therapeutic potential of polyphenols in cardiac fibrosis[J]. Front Pharmacol, 2018, 9:122.
[15] Fisher SA, Doree C, Mathur A, et al. Cochrane corner: stem cell therapy for chronic ischaemic heart disease and congestive heart failure[J]. Heart, 2018, 104(1):8-10.
[16] Hinderer S, Brauchle E, Schenke-Layland K. Generation and assessment of functional biomaterial scaffolds for applications in cardiovascular tissue engineering and regenerative medicine[J]. Adv Healthc Mater, 2015, 4(16):2326-2341.
[17] Wang H, Shi J, Wang Y, et al. Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction[J]. Biomaterials, 2014, 35(13):3986-3998.
[18] Piccirillo G, Bochicchio B, Pepe A, et al. Electrospun poly-l-lactide scaffold for the controlled and targeted delivery of a synthetically obtained diclofenac prodrug to treat actinic keratosis[J]. Acta Biomater, 2017, 52:187-196.
[19] Lakshmanan R, Maulik N. Development of next generation cardiovascular therapeutics through bio-assisted nanotechnology[J]. J Biomed Mater Res B Appl Biomater, 2018, 106(5):2072-2083
[20] Wang RM, Christman KL. Decellularized myocardial matrix hydrogels: in basic research and preclinical studies[J]. Adv Drug Deliv Rev, 2016, 96:77-82.
[21] Lewis FC, Kumar SD, Ellison-Hughes GM. Non-invasive strategies for stimulating endogenous repair and regenerative mechanisms in the damaged heart[J]. Pharmacol Res, 2018, 127:33-40.
[22] Korf-Klingebiel M, Reboll MR, Klede S, et al. Corrigendum: myeloid-derived growth factor(C19orf10)mediates cardiac repair following myocardial infarction[J]. Nat Me, 2016, 22(4):446.
[23] Shyu KG. The role of endoglin in myocardial fibrosis[J]. Acta Cardiol Sin, 2017, 33(5):461-467.
[24] Miyagawa S, Domae K, Yoshikawa Y, et al. Phase Ⅰ clinical trial of autologous stem cell-sheet transplantation therapy for treating cardiomyopathy[J]. J Am Heart Assoc, 2017, 6(4):e003918.
[25] Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review[J]. JAMA Cardiol, 2016, 1(7):831-841.
[26] Thies RS, Murry CE. The advancement of human pluripotent stem cell-derived therapies into the clinic[J]. Development, 2015, 142(20):3614.
[27] Mohsin S, Siddiqi S, Collins B, et al. Empowering adult stem cells for myocardial regeneration[J]. Circ Res, 2011, 109(12):1415-1428.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81270310)
通信作者:刘巍,E-mail:doctor-liuwei@126.com
更新日期/Last Update: 2020-10-15